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Abstract: Parathyroid hormone (PTH) is a major player in 
phosphocalcic metabolism and its measurement is very 
important for the correct diagnosis and treatment of sev-
eral diseases. PTH determination represents the paradigm 
of quality in laboratory medicine as many variables in the 
pre-, intra-, and post-analytical phases strongly affect the 
value of the clinical information. Analytical determina-
tion of PTH has been rendered difficult by the presence, 
in the circulation, of truncated fragments that can cross-
react with the antibodies used for its determination. In 
addition, pre-analytical phase is complicated by the lack 
of stability of the peptide and the best sample to use for 
its determination remains controversial, as well as sample 
handling and storage. PTH secretion is also affected by 
circadian and seasonal rhythms and by physical exercise. 
Finally, from the post-analytical perspective, establish-
ment of reliable reference ranges requires further efforts 
as the selection criteria for reference subjects should take 
into consideration new variables such as gender, race and 
vitamin D levels. Finally, clinical guidelines have recently 
revised and improved the criteria for a correct interpreta-
tion of PTH values.
Keywords: calcium metabolism; clinical guidelines; 
diurnal and seasonal rhythms; parathyroid hormone; 
 reference ranges; sample of choice; stability.
Introduction
The measurement of the human parathyroid hormone 
(PTH) represents the paradigm of quality in laboratory 
medicine as many variables in the pre-, intra-, and post-
analytical phases strongly affect the value of the clinical 
information (Table 1). In fact, in addition to analytical 
problems due to the presence in circulation of different 
molecular species, PTH results are influenced in the pre-
analytical phase by diurnal and seasonal rhythms and 
poor standardization of sample collection (time, sample 
of choice, preservation and storage conditions). In the 
post-analytical phase, the interpretation varied over time 
according to different guidelines. However, as recently 
highlighted by Souberbielle et al. “the quality of the PTH 
assay is of paramount importance because it contributes to 
the therapeutic decision” [1] and, therefore, major efforts 
should be done to improve the accuracy and reliability of 
laboratory practice.
PTH secretion and action
The PTH gene is located on the short arm of chromosome 11 
[2]. PTH is synthesized as a large polypeptide (pre-pro PTH) 
containing 115 amino acids that undergoes two successive 
proteolytic cleavages to yield the 84 amino-acids PTH, the 
main form of the hormone stored in and secreted from 
the parathyroid glands. PTH is a major player in calcium 
metabolism. Decreases in plasma ionized calcium (Ca2+) 
are detected by the calcium-sensing receptor, a G-protein 
coupled receptor of 1078 amino acids which consists of a 
large N-terminal extracellular domain, seven transmem-
brane helical domains and an intracellular C-tail segment 
[3]. This receptor is present in the organs that secrete 
calcium-regulating hormones (the parathyroid glands 
and the C-cells of the thyroid) and in the target tissues of 
these hormones (renal tubules of the kidney, bone and 
intestine). It plays a key role in the control, by the ionized 
calcium levels, of PTH secretion and in the renal reabsorp-
tion of calcium. PTH acts primarily on kidney and bone 
where it binds to cells expressing the type 1 PTH/PTHrP 
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receptor (PTH1R). This G-protein coupled receptor is also 
characterized by seven transmembrane domains. When it 
binds PTH, the PTH/PTHrP receptor transduces its signal 
through activation of protein kinases A and C pathways [4]. 
We now know that the very first N-terminal amino-acids of 
the PTH molecule are necessary for this interaction [5]. In 
the kidney, PTH stimulates the reabsorption of calcium in 
the distal tubule and the activity of the 1-alpha hydroxy-
lase in the renal proximal tubule, thus enhancing the syn-
thesis of 1,25 dihydroxy-vitamin D. This active metabolite 
of vitamin D increases the intestinal absorption of calcium 
(and phosphorus) and exerts an endocrine feedback on 
the secretion of the peptide. PTH also decreases the renal 
reabsorption of phosphate in the proximal tubule (which 
decreases serum phosphate) through the endocytosis of 
the apical sodium dependant cotransporter Npt2a [6]. In 
bone, PTH can induce a rapid release of calcium from 
the matrix. At longer term, PTH induces changes in Ca 
metabolism by its action on osteoblasts and indirectly on 
osteoclasts. Briefly, a continuous production of PTH will 
stimulate bone resorption by enhancing the transforma-
tion of pre-osteoclasts into active osteoclasts, through 
the osteoblasts. Indeed, PTH stimulates the osteoblastic 
production of the receptor activator for nuclear factor κ 
B ligand (RANK-L) together with Interleukin-1 and 1,25 
(OH)2-vitamin D and inhibits the expression of osteopro-
tegerin, an inhibitor of the RANK receptor. Precisely, this 
receptor is present on the surface of the pre-osteoclasts 
and its activation by the RANK-L will induce the transfor-
mation of pre-osteoclasts into active osteoclasts.
PTH metabolization, performed in the liver, will 
release different amino-truncated PTH fragments in the 
circulation. These fragments are generally called C-ter-
minal fragments because they have kept the carboxyl-
terminal part of the peptide [7]. They are cleared from 
the circulation through the kidneys, as PTH itself [8], 
thus accumulating in the blood of patients suffering from 
chronic kidney diseases (CKD) [9]. These fragments have a 
higher half-life than the (1-84) PTH itself.
PTH determination
The presence, in the circulation, of the fully, untrun-
cated, active peptide next to these truncated fragments 
have rendered PTH determination very complicated [10]. 
Indeed, what we call now “intact” PTH assays or second- 
generation assays, recognize both 1-84 PTH and large 
N-truncated fragments, that used to be called “7-84”-PTH 
(even if the presence in plasma of the 7-84 fragment has 
recently been challenged [11]). Intact PTH assays remain 
however the most used ones worldwide.
Third generation PTH assays are specific for the 1-84 
PTH and do not cross-react with the C-terminal fragments, 
but they cross-react with a N-terminal molecular form of 
PTH (amino-PTH), a PTH phosphorylated on the serine 
in position 17, overproduced in parathyroid carcinoma 
[12, 13] and in rare cases of severe primary hyperparathy-
roidism [14]. These assays are not as used as the “intact” 
PTH ones, since two manufacturers only (namely DiaSorin 
and Roche) present an automated version of these assays, 
even not available in every country.
Finally, since 1984, it is known that the PTH peptide 
contains two methionines in position 8 and 18 and that 
these methionines can be oxidized. Oxidation of these 
methionines leads to a loss of biological activity of the 
peptide [15]. The different immunoassays available on 
the market do not make any distinction between the oxi-
dized and non-oxidized PTH and thus cross react with 
Table 1: Variables in the pre-, intra-, and post-analytical phases that strongly affect the value of the clinical information of a PTH result. 
Pre-analytical phase   Intra-analytical phase   Post-analytical phase
Short-term PTH stability   Cross-reactivity with fragments accumulating in kidney 
diseases for 2nd generation PTH assays
  Establishment of reference ranges in 
vitamin D replete subjects
Long-term PTH stability   Cross reactivity of amino-PTH (hyperproduced in 
parathyroid carcinoma) with 3rd generation PTH assays
  Large intra-individual variation
Choice of serum or EDTA plasma   Oxidized and non-oxidized PTH recognized by the 
assays whereas non-oxidized PTH is the only active 
form
  Impact of ethnicity on reference range
Time of sampling   Simultaneous need to have PTH and calcium to 
correctly interpret PTH results
  Impact of mean calcium intakes on 
the reference range
Short half-life of the peptide in 
the circulation
    Impact of age on the reference range
Fasting status    
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this inactive form. This may be of particular importance 
in hemodialyzed patients, who suffer from intense oxi-
dative stress and, recently, some results have shown that 
non-oxidized PTH correlated better with clinical events 
[16, 17], leading to the question on the potential interest 
to develop a fourth-generation PTH assay, which would 
only recognize the non-oxidized (1-84) PTH [18]. However, 
to our knowledge, no studies have ever proved that this 
oxidation occurred in vivo and not in vitro, which could be 
expected if the samples were not treated properly in due 
time. Indeed, the pre-analytical phase is of major impor-
tance to obtain reliable PTH results.
PTH determination: the pre- 
analytical phase
Pre-analytical handling of samples
PTH is known as being quite unstable and many papers 
have been published on PTH stability. The debate is also 
quite intense regarding the vehicle in which blood should 
be drawn for PTH determination, either EDTA-containing 
or gel-containing blood collection devices. Prior to discuss 
these important points, we should remember that the WHO 
has already published guidelines in 2002 regarding the use 
of anticoagulants in laboratory investigations [19]. These 
guidelines state the advantage of using serum or plasma 
and among the points that are mentioned, we can summa-
rize the ones that may impact PTH determination as follows:
Advantages of using plasma
1) Time saving: Plasma samples can be centrifuged 
directly after sample collection, unlike serum, in 
which coagulation is completed after 30 min.
2) Higher yield: 15%–20% more in volume of plasma than 
of serum can be isolated from the same volume of blood.
3) Prevention of coagulation-induced interferences: 
coagulation in primary and secondary tubes that were 
already centrifuged, may block suction needles of the 
analyzers when serum tubes are used.
Disadvantages of plasma over serum
1) The addition of anticoagulants may interfere with cer-
tain analytical methods or change the concentration 
of the constituents to be measured (contamination 
with cations: NH4+, Li+, Na+, K+).
2) Assay interference caused by metals complexing with 
EDTA (e.g., inhibition of alkaline phosphatase activ-
ity by zinc binding, inhibition of metallo-proteinases, 
inhibition of metal-dependent cell activation in func-
tion tests, binding of calcium (ionized) to heparin – 
and we may also add to EDTA).
3) Interference by fibrinogen in heterogeneous 
immuno assays.
If these guidelines are very useful, they may not decipher 
if EDTA plasma should be preferred over serum: indeed, in 
favor of EDTA, we will speed up the turnaround time (TAT) 
by reducing the clotting time. This can be of great interest 
in clinical situations where a PTH result must be reported 
as soon as possible by the laboratory, like in parathyroid 
surgery, when the surgeon needs to objective the drop of 
PTH before ending the operation. One should admit that, 
besides this particular situation, the vast majority of PTH 
determinations can support to wait the clotting time of 
the sample. We think that the major advantage of using 
serum is that calcium concentrations can be evaluated 
on the same sample. Indeed, calcium concentrations are 
mandatory to interpret a PTH value. Thus, by using EDTA 
samples, two samples would be needed, one EDTA for 
PTH and one serum tube for calcium. KDIGO guidelines 
also recommend to measure bone alkaline phosphatase 
concentrations (bAP) next to PTH [20]. Most of bAP assays 
actually measure the activity of the enzyme (even if they 
report mass units) [21] and, as stated in the WHO guide-
lines, alkaline phosphatase is inhibited by EDTA. Thus, 
two samples would be needed once again. Finally, excess 
EDTA in underfilled tubes can inhibit signal production 
in methods that use alkaline phosphatase [22]. In con-
clusion, excepted for the particular case of parathyroid 
surgery, we believe that serum should be preferred over 
EDTA for routine testing.
PTH stability in EDTA or serum should be the para-
mount of our concerns. As previously stated, many papers 
have been published on the topic and a recent systematic 
review on the subject has been published in this journal 
[23]. As the authors of this review, we have to complain 
about the tremendous variability – due to both pre- and 
intra-analytical variables – between the studies, which 
does not help to decide whether EDTA should be preferred 
over serum or not. Our major concerns are mainly the defi-
nition of the “zero” point and the cut-off below which one 
can decide whether there is a degradation of the peptide 
or not. Regarding the “zero” point, most of the studies 
on PTH stability have used, as comparator, a sample that 
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has been immediately frozen at −20 °C [24–31] or at −80 °C 
 [32–34], but few of them used an unfrozen sample, immedi-
ately assayed after centrifugation [22, 35–37]. The authors 
that used a frozen sample as T0 did that on purpose to run 
all the samples in one batch in order to reduce the CV, but 
it is unclear if this could have some consequences on the 
final results.
Even more important is the cut-off below which it was 
decided if the peptide remained stable or not. Basically, 
two approaches have been followed by the authors: the 
purely statistical approach and the “biological” approach.
In the first approach, a statistical test was performed 
to see if there was a difference before/after storage or not, 
whatever the percentage of degradation. Very few authors 
used the “biological” approach, as recommended by the 
WHO guideline that defines the “maximum permissible 
instability”, which should be smaller than half of the total 
error derived from the sum of biological and technical 
variability [19]. This guideline also defines the permissi-
ble storage time as the period of time of which the stability 
requirement of 95% of the samples is met. Oddoze et al. 
have also elegantly defined a total change limit (TCL) as 
the square root of [(2.77*CVa)²+(0.5*CVb)²], with CVa and 
CVb being the analytical and biological coefficients of var-
iation, respectively [34]. Accordingly, if we take the ana-
lytical and biological CV of PTH as determined by second 
and third generation by Gardham et  al. [38] or by our 
group [39], the WHO limit should be  < 11.4 or 8.05% for the 
second generation and  < 14.02 and 9.7% for the third gen-
eration. The TLC should be  < 14.5 and 9.4% for the second 
and  < 13.7 and 16.7% for the third generation. As the TLC 
has been defined according to the acceptable change limit 
defined in the ISO 5725-6 [40] and takes into considera-
tion a statistical factor Z ( = 1.96*√2) for a 95% confidence 
interval for a bidirectional change as well as half of the 
intra-individual variation, we think that the results of the 
TLC should be used to set up PTH stability.
Taking all this information into consideration, it 
remains difficult to set up one’s mind on PTH stability. In 
plasma or serum, PTH does not seem to be degraded when 
conserved for long periods ( > 1 year) at −20 °C or −80 °C. 
However, for short-term conservation at room tempera-
ture, EDTA seems better than serum, even if this advan-
tage tends to disappear when samples are kept at +4 °C.
Time of sampling
Hanon et al. have recently reviewed the circadian variation 
of PTH [23]. Briefly, PTH follows a bimodal rhythm, with a 
nocturnal acrophase a mid-morning nadir and a smaller 
afternoon peak, even if all the studies do not totally agree 
on peak times. Sensu stricto, it may thus be logical to 
collect samples for PTH determination during the nadir 
phase, i.e., between 10:00 and 16:00 [23, 41]. To correctly 
interpret PTH levels, we have however to consider calcium 
(and phosphate) concentrations. Surprisingly, very few 
papers have thoroughly studied the impact of a meal 
on calcium levels. Statland et al. have noted that a meal 
could increase calcium by a mean value of 0.04 mmol/L 
[42]. Even if this increase may seem of little importance, it 
is higher than the minimal allowable bias for total serum 
calcium and a patient suffering from mild hypocalcemia 
could become normocalcemic. In the same vein, a patient 
presenting calcium levels in the upper normal range could 
be considered as mildly hypercalcemic. Finally, the meal 
used in this study was not particularly rich in calcium as it 
consisted of 2–5 sandwiches (pork, herring, cheese) and a 
beverage (soda, beer or coffee). A breakfast could contain 
more calcium if milk or a dairy product is consumed and 
it is well known that large calcium doses (like the ones 
used in the calcium loading test) significantly decrease 
PTH levels.
Serum phosphate concentrations can also be influ-
enced by a meal. In the same study, the participants 
increased their mean phosphate concentrations by 28%, 
which far exceeds the minimal bias of 5.1%. Furthermore, 
phosphatemia is subject to important circadian variations. 
Thus, a serum phosphate concentration is frequently 
measured together with calcium and PTH. These are 
other reasons to recommend a morning blood sample in 
a fasting state.
For all these considerations, in non-hemodialyzed 
patients, we still recommend to measure PTH levels in 
fasting status (generally earlier than 10 AM).This will also 
be mandatory if PTH levels are measured together with 
bone markers like CTX or PINP.
PTH determination: the post- 
analytical phase
An elevated serum PTH concentration (i.e., above the 
upper normal value) reflects either a secondary hyperpar-
athyroidism (SHPT) when associated to hypocalcemia, or 
a primary hyperparathyroidism (PHPT) when associated 
with hypercalcemia. In normocalcemic patients, an ele-
vated PTH necessitates a differential diagnosis between 
SHPT and normocalcemic PHPT which may be more chal-
lenging [43]. In hemodialyzed patients, KDIGO guidelines 
recommend to maintain the serum PTH levels within 
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twice to 9 times the upper normal limit of the reference 
range [20]. Accordingly, the definition of the upper limit of 
the PTH normal range is of prime importance. This raises 
the question of the inclusion/exclusion criteria which 
should be applied when recruiting a reference popula-
tion to establish PTH normal values. Exclusion criteria for 
this population can be defined as any situation possibly 
inducing an increase or a decrease in PTH concentration. 
Among these conditions, low serum 25-hydroxyvitamin D 
(25OHD) concentration is highly frequent in the general 
population [44] and should thus be prevalent in an appar-
ently healthy group recruited to establish normal PTH 
values. Excluding subjects with vitamin D insufficiency 
from a reference population for serum PTH reference 
values seems thus logical and has been strongly recom-
mended in the two most recent guidelines on the diagno-
sis and management of asymptomatic PHPT [45, 46]. We 
have also demonstrated in several studies that excluding 
subjects with a low serum 25OHD concentration from a 
reference population decreased the upper normal limit 
for serum PTH by 20%–35%, depending on the assay 
considered [44, 47–50]. The obvious consequence is that 
above-normal concentrations will be found more often in 
clinical practice. On the one hand, this will improve the 
diagnostic sensitivity of PTH measurements as serum PTH 
will be more frequently elevated in patients with either 
a true SHPT or PHPT. On the other hand, by decreasing 
PTH upper reference limit, one could argue that it could 
potentially reduce its diagnostic specificity (i.e., find a 
“high” PTH concentration in patients without any reason 
for an increased PTH secretion). However, we have already 
shown that establishing PTH reference ranges in vitamin 
D-replete subjects did not induce a decrease in diagnos-
tic specificity, as there was no more than the expected 3% 
of above-normal PTH concentrations in 360 consecutive 
osteoporotic patients for whom no reasons for high PTH 
were found after examining their medical chart and exten-
sive biological evaluation [51].
Besides 25(OH)D levels, renal function should also be 
taken into consideration when establishing PTH reference 
values. Indeed, PTH generally rises when estimated glo-
merular filtration rate (eGFR) is below 60 mL/min/1.73 m² 
[20]. As a decreased renal function may be present, but 
ignored, in some apparently healthy subjects (especially 
in those aged more than 60 years) a creatinine measure-
ment to determine the eGFR is mandatory when estab-
lishing reference ranges. Other parameters like age, BMI, 
dietary calcium intakes and ethnicity may also influence 
PTH reference ranges and further studies are needed to 
determine whether reference PTH values should be strati-
fied according to some of these parameters.
Analytical phase: standardization 
of PTH assays
Standardization of PTH assays is of importance to reduce 
inter-method variability [52], particularly in hemodia-
lyzed patients [53]. An IFCC workgroup, in which repre-
sentatives of relevant clinical and scientific professional 
organization and manufacturers of most PTH immunoas-
says are present is thus working on the current status of 
PTH measurement and on the identification of priorities 
for improvement. The group has proposed that the 95/646 
WHO International Standard Parathyroid hormone 1-84, 
established by the Expert Committee on Biological Stand-
ardisation of the WHO in October 2009, become the refer-
ence standard for PTH assays calibration. This standard is 
made of recombinant, 1-84, human PTH and has recently 
been shown to be commutable [54]. The traceability of 
the assays to the WHO International Standard could be 
achieved with the recently published LC-MS/MS method 
allowing the quantification of serum 1-84 PTH after trypsic 
digestion [55]. In our opinion, however, a total standardi-
zation of PTH assays can only be achieved with third gen-
eration PTH assays and not with the second generation 
ones. Indeed, for these latter, even if standardization can 
theoretically be achieved in healthy populations, this will 
probably not be the case for CKD patients due to different 
cross- reactivity of the antibodies with the 7-84 PTH.
Conclusions
The debate on PTH is still active and many studies should 
still be undertaken to clarify some essential (but basic) 
points like stability, type of sample and time of sampling. 
Two of the authors (EC and JCS) participate to the IFCC Sci-
entific Division Working Group on PTH, but totally disa-
gree with the conclusions published by other experts that 
signed on behalf of this group [23]. For us, and in contrast 
with these colleagues, serum seems the most appropriate 
to measure PTH, mainly because it allows the simultane-
ous determination of calcium. PTH should also be meas-
ured in fasting status and good reference ranges should 
be established in a multicenter and multiethnic study in 
vitamin D-replete subjects with a normal renal function.
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